10 January 2018 - - US-based rare disease therapeutics company ArTara has appointed Randall Marshall, MD as chief medical officer and president of research and development, the company said.
Marshall will join as a co-founder of ArTara to provide scientific and medical leadership for research and business development activities. He brings over 30 years' experience across all aspects of clinical research including translational, Phase 1-3, and post-marketing studies in academia, start-up, and mid-sized biopharmaceutical companies.
Prior to joining ArTara, Marshall led Retrophin, Inc.'s development of fosmetpantotenate, a replacement therapy for PKAN, an ultra-rare neurodegenerative disease. Under Marshall's leadership the program moved from first-in-man to pivotal trial in 2 years and was granted a special protocol assessment from FDA.
Marshall's previous experience includes leadership of multiple drug development programs at companies such as Neurovance, Alkermes and Sepracor/Sunovion.
Marshall's career began in academia at Columbia University, where he was an Associate Professor specializing in clinical trials in CNS indications including PTSD.
ArTara is focused on optimizing therapeutics for patients suffering from rare diseases where there is a significant unmet need. The company's initial focus is on rare gastrointestinal, metabolic, circulatory, and neurological disorders.